Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
Sponsor: M.D. Anderson Cancer Center
Terminated
Low accrual
Other terminated trials from M.D. Anderson Cancer Center
Other Leiomyosarcoma trials with similar outcome
A PHASE2 clinical study on Leiomyosarcoma and Uterine Neoplasm, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Terminated PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .